{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T15:40:05Z","timestamp":1763480405126,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2020.100272","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T21:23:45Z","timestamp":1607635425000},"page":"100272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma"],"prefix":"10.1016","volume":"26","author":[{"given":"Manasi","family":"Sheth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinnie","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2020.100272_bib0001","unstructured":"Pazdur, Richard, Wagman, Lawrence, Camphausen, Kevin, Hoskins, William, Cancer Management: a Multidisciplinary Approach, 11th Edition, 2008."},{"issue":"5","key":"10.1016\/j.ctarc.2020.100272_bib0002","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.suc.2014.07.013","article-title":"Epidemiology, risk factors, prevention, and early detection of Melanoma","volume":"94","author":"Azoury","year":"2014","journal-title":"Surg Clin North Am"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100272_bib0003","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/jcm8030368","article-title":"The clinical trial landscape for Melanoma therapies","volume":"8","author":"Wr\u00f3bel","year":"2019","journal-title":"J Clin Med."},{"issue":"9","key":"10.1016\/j.ctarc.2020.100272_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153082","article-title":"Nanomicellar-curcumin exerts its therapeutic effects via affecting angiogenesis, apoptosis, and T cells in a mouse model of Melanoma Lung Metastasis","volume":"216","author":"Mardani","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100272_bib0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13402-020-00501-z","article-title":"CXCL-10: a new candidate for melanoma therapy?","volume":"43","author":"Bagheri","year":"2020","journal-title":"Cell Oncol (Dordr)"},{"key":"10.1016\/j.ctarc.2020.100272_bib0006","doi-asserted-by":"crossref","unstructured":"Pourhanifeh M.H., Abbaszadeh-Goudarzi K., Goodarzi M., et\u00a0al. Resveratrol: a new potential therapeutic agent for melanoma? [published online ahead of print, 2019 Dec 11]. Curr Med Chem. 2019; 10.2174\/0929867326666191212101225. doi:10.2174\/0929867326666191212101225.","DOI":"10.2174\/0929867326666191212101225"},{"key":"10.1016\/j.ctarc.2020.100272_bib0007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.canlet.2018.01.029","article-title":"The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model","volume":"419","author":"Mirzaei","year":"2018","journal-title":"Cancer Lett"},{"issue":"7","key":"10.1016\/j.ctarc.2020.100272_bib0008","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/bmm-2019-0567","article-title":"Circular RNAs: new genetic tools in Melanoma","volume":"14","author":"Hallajzadeh","year":"2020","journal-title":"Biomark Med"},{"issue":"6","key":"10.1016\/j.ctarc.2020.100272_bib0009","first-page":"488","article-title":"Treatment of Metastatic Melanoma: an Overview","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ctarc.2020.100272_bib0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100272_bib0011","doi-asserted-by":"crossref","first-page":"W221","DOI":"10.2214\/AJR.09.3928","article-title":"New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy","volume":"195","author":"Nishino","year":"2010","journal-title":"AJR Am J Roentgenol"},{"volume":"48","year":"1979","key":"10.1016\/j.ctarc.2020.100272_bib0012"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100272_bib0013","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100272_bib0014","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ctarc.2020.100272_bib0015","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctarc.2020.100272_bib0016","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma [published correction appears in N Engl J Med. 2010 Sep 23;363(13):1290]","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ctarc.2020.100272_bib0017","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/307059","article-title":"Combination therapies for the treatment of advanced melanoma: a review of current evidence","volume":"2014","author":"Voskoboynik","year":"2014","journal-title":"Biochem Res Int"},{"issue":"9839","key":"10.1016\/j.ctarc.2020.100272_bib0018","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ctarc.2020.100272_bib0019","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ctarc.2020.100272_bib0020","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"371","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctarc.2020.100272_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2015.33.15_suppl.tps9093","article-title":"SWOG S1320: a randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E\/k mutant melanoma","volume":"33","author":"Algazi","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220301076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220301076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:21:07Z","timestamp":1762842067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294220301076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":21,"alternative-id":["S2468294220301076"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100272","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100272"}}